New insider activity at Eli Lilly & Co ( (LLY) ) has taken place on November 6, 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Lilly Endowment Inc, a significant shareholder of Eli Lilly & Co, has recently sold a total of 219,474 shares of the company’s stock. The transactions were executed in two separate sales, with the first involving 40,432 shares valued at $38,473,299, and the second comprising 179,042 shares worth $167,091,432. These sales collectively amount to a substantial divestment from Eli Lilly & Co by Lilly Endowment Inc.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Outperform.
Eli Lilly & Co’s strong revenue growth and market share gains, highlighted in the earnings call, are significant positives. The technical indicators also suggest bullish momentum. However, high valuation and leverage, along with declining cash flow metrics, present potential risks. Overall, the stock is well-positioned but requires careful monitoring of financial leverage and cash flow management.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly & Co
YTD Price Performance: 20.64%
Average Trading Volume: 4,595,024
Technical Sentiment Signal: Buy
Current Market Cap: $857.3B